Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study

被引：0
|
作者：
Orlandi, Armando
Pinto, Carmine
Calegari, Maria Alessandra
Normanno, Nicola
Maiello, Evaristo
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, M. Giulia
Bergamo, Francesca
Tonini, Giuseppe
Tamberi, Stefano
Avallone, Antonio
Latiano, Tiziana Pia
Rosati, Gerardo
Pazzola, Antonio
Ballestrero, Alberto
Zaniboni, Alberto
Formica, Vincenzo
Barone, Carlo
机构：
[1] Fdn Policlini Univ A Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[2] Azienda USL IRCCS Reggio Emilia, Med Oncol Unit, Reggio Emilia, Italy
[3] Fdn Policlin Univ Agostino Gemelli, Med Oncol Unit, IRCCS, Rome, Italy
[4] G Pascale Foudat, Natl Canc Inst Naples, Brusciano, Italy
[5] Fdn IRCSS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[6] Careggi Univ Hosp, Clin Oncol Unit, Dept Expt & Clin Med, Florence, Italy
[7] Azienda Osped ARNAS Garibaldi, Med Oncol, Catania, CT, Italy
[8] Ist Europeo Oncol, Milan, Italy
[9] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Med Oncol 1, Padua, Italy
[10] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[11] Oncol Unit, Osped Santa Maria Croci, Ravenna, Italy
[12] Fondazione G Pascale Napoli, Ist Nazl Tumori, Naples, Italy
[13] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[14] Azienda Osped S Carlo, Potenza, Italy
[15] Osped Civili SS Annunziata, Dept Med Oncol, Sassari, Italy
[16] Univ Genoa, Genoa, Italy
[17] CdC Poliambulanza, Brescia, Italy
[18] Univ Rome, Med Oncol Unit, Tor Vergata Clin Ctr, Rome, RM, Italy
[19] Fdn Policlin Univ A Gemelli IRCCS Roma, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3603
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [2] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
  • [4] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Rachiglio, Anna Maria
    Maglietta, Giuseppe
    Damato, Angela
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Tonini, Giuseppe
    Rosati, Gerardo
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Barone, Carlo
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
    Antoniotti, Carlotta
    Cremolini, Chiara
    Loupakis, Fotios
    Bergamo, Francesca
    Grande, Roberta
    Tonini, Giuseppe
    Garattini, Silvio Ken
    Masi, Gianluca
    Battaglin, Francesca
    Lucchesi, Sara
    Salvatore, Lisa
    Corsi, Domenico C.
    Di Fabio, Francesca
    Banzi, Maria
    Sensi, Elisa
    Tomcikova, Daniela
    Fontanini, Gabriell
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.
    Sobrero, Alberto F.
    Lenz, Heinz-Josef
    Eng, Cathy
    Scheithauer, Werner
    Middleton, Gary William
    Chen, Wen-Feng
    Esser, Regina
    Nippgen, Johannes
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew
    Salem, Mohamed E.
    Sanoff, Hanna Kelly
    Triglianos, Tammy
    McRee, Autumn Jackson
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study
    Jiang, Tao
    Chen, Hao
    Zheng, Jianwei
    Du, Bin
    Yang, Baoyu
    Liu, Qing
    Zhong, Dongta
    Wang, Xinli
    Wang, Han
    Lin, Mengxin
    Lai, Jinhuo
    Hou, Peifeng
    Lin, Xiaoyan
    ADVANCES IN THERAPY, 2020, 37 (06) : 2829 - 2840
  • [9] Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study
    Tao Jiang
    Hao Chen
    Jianwei Zheng
    Bin Du
    Baoyu Yang
    Qing Liu
    Dongta Zhong
    Xinli Wang
    Han Wang
    Mengxin Lin
    Jinhuo Lai
    Peifeng Hou
    Xiaoyan Lin
    Advances in Therapy, 2020, 37 : 2829 - 2840
  • [10] Rechallenge with cetuximab 1 irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with
    Daniele, Rossini
    Daniele, Santini
    Chiara, Cremolini
    Lisa, Salvatore
    Sara, Lonardi
    Emanuela, Dell' Aquila
    Giuseppe, Aprile
    Fotios, Loupakis
    Bruno, Vincenzi
    Francesca, Battaglin
    Vanessa, Buoro
    Emiliano, Tamburini
    Deborah, Basile
    Domenico, Corsi
    Iacopo, Fioroni
    Gianluca, Masi
    Carlotta, Antoniotti
    Beatrice, Borelli
    Marzia, Del Re
    Giuseppe, Tonini
    Alfredo, Falcone
    ANNALS OF ONCOLOGY, 2017, 28
12345